Direct healthcare costs of chronic kidney disease management in Italy: what costâsavings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesisâstimulating agents?
Ingrasciotta, Ylenia, Sultana, Janet, Formica, Dario, Ientile, Valentina, Aiello, Andrea, Chinellato, Alessandro, Tari, Daniele Ugo, Gini, Rosa, Pastorello, Maurizio, Scondotto, Salvatore, Cananzi, PaJournal:
Pharmacoepidemiology and Drug Safety
DOI:
10.1002/pds.5152
Date:
October, 2020
Fichier:
PDF, 2.04 MB
2020
File converter
Plus de résultats de recherche
More benefits 
